PJWM
VRTX icon

Philip James Wealth Mangement’s Vertex Pharmaceuticals VRTX Stock Holding History

Philip James Wealth Mangement’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Sell
2,570
-58
-2% -$27K 0.13% 77
2025
Q4 		$1.19M Sell
2,628
-1,431
-35% -$617K 0.14% 79
2025
Q3 		$1.59M Sell
4,059
-399
-9% -$167K 0.19% 75
2025
Q2 		$1.98M Buy
4,458
+1,467
+49% +$676K 0.25% 66
2025
Q1 		$1.45M Buy
+2,991
New +$1.39M 0.18% 71

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Philip James Wealth Mangement's VRTX Position: Q1 2026 in Review

Philip James Wealth Mangement reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, selling an estimated $27K and leaving 2,570 shares worth $1.15M. The position accounts for 0.13% of the portfolio, ranked #77.

Philip James Wealth Mangement first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.98M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Philip James Wealth Mangement held 2,570 shares of Vertex Pharmaceuticals worth $1.15M as of Q1 2026.
  • Philip James Wealth Mangement sold 58 Vertex Pharmaceuticals shares in Q1 2026, an estimated $27K.
  • Vertex Pharmaceuticals made up 0.13% of Philip James Wealth Mangement's portfolio in Q1 2026, its #77 holding.
  • Philip James Wealth Mangement first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Philip James Wealth Mangement's Vertex Pharmaceuticals position peaked at $1.98M in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Philip James Wealth Mangement's 13F filing for Q1 2026, filed 28 Apr 2026.